Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 2/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | EIF4EBP1 | Q13541 | 9/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792883 | 0.92 | PLK1 (0.33) | PDPK1CDK2PLK1 | |
| SCHEMBL6792282 | 0.92 | RORC (0.34) | RORCEIF4EBP1PDPK1CDK2PLK1 | |
| SCHEMBL6793459 | 0.91 | PTGDR2 (0.33) | RORCPDPK1CDK2PLK1 | |
| SCHEMBL1655969 | 0.91 | S1PR1 (0.37) | PDPK1CDK2PLK1 | |
| SCHEMBL6791786 | 0.90 | PLK1 (0.32) | PDPK1CDK2PLK1 | |
| SCHEMBL1658164 | 0.89 | PTGDR2 (0.37) | — | |
| SCHEMBL6799702 | 0.88 | PTGDR2 (0.32) | PDPK1CDK2PLK1PARP1 | |
| SCHEMBL1656590 | 0.88 | GABRA1 (0.35) | PDPK1CDK2PLK1 | |
| SCHEMBL6794891 | 0.88 | RORC (0.34) | RORCPDPK1CDK2PLK1 | |
| Trifluoroacetic Acid SCHEMBL6794900 | 0.87 | RORC (0.34) | PTGIRPTGDRRORCPDPK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | PTGIR 865/4885PTGDR 661/4885RORC 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.